Davis Hugh M. 4
4 · Aclaris Therapeutics, Inc. · Filed Dec 4, 2025
Insider Transaction Report
Form 4
Davis Hugh M.
DirectorPresident and COO
Transactions
- Exercise/Conversion
Common Stock
2025-12-02+26,750→ 26,750 total - Exercise/Conversion
Restricted Stock Units
2025-12-02−26,750→ 80,250 total→ Common Stock (26,750 underlying)
Footnotes (2)
- [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
- [F2]The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of December 2, 2024 (in each case rounded down to the nearest whole share, except for the last vesting installment), subject to the Continuous Service (as defined in the Issuer's 2024 Inducement Plan) of the Reporting Person as of each such date.